Crispin R Dass obtained his B App. Sci. (Hons) and PhD from Charles Sturt University, Australia. He has 22 years of basic and applied research in cancer. He has worked on bigpharma projects (Amgen, Novartis, Glaxo-Wellcome, Johnson & Johnson). He has published in Nature Medicine, Journal of the National Cancer Institute, Journal of Controlled Release and Biomaterials. He has published 147 papers to date, 165 conference presentations, a h-index of 33, with total number of citations for his papers at ~3400. He has also reviewed original research papers in New England Journal of Medicine, Lancet and Nature Communications. Crispin R Dass obtained his B App. Sci. (Hons) and PhD from Charles Sturt University, Australia. He has 22 years of basic and applied research in cancer. He has worked on bigpharma projects (Amgen, Novartis, Glaxo-Wellcome, Johnson & Johnson). He has published in Nature Medicine, Journal of the National Cancer Institute, Journal of Controlled Release and Biomaterials. He has published 147 papers to date, 165 conference presentations, a h-index of 33, with total number of citations for his papers at ~3400. He has also reviewed original research papers in New England Journal of Medicine, Lancet and Nature Communications.

Medicine and orthopedics